Nakamura Kenji, Okubo Kazutoshi, Takahashi Takeshi, Mitsumori Kenji, Ishigaki Takashi, Ohnishi Hiroyuki
Department of Urology Osaka Red Cross Hospital Osaka Japan.
Department of Radiology Osaka Red Cross Hospital Osaka Japan.
IJU Case Rep. 2018 Nov 26;2(1):30-33. doi: 10.1002/iju5.12032. eCollection 2019 Jan.
A radiation recall reaction in previously irradiated lungs is known as radiation recall pneumonitis. We encountered a rare case of radiation recall pneumonitis induced by nivolumab 9 months after palliative radiotherapy to the ribs.
The patient was a 69-year-old woman with renal cell carcinoma. She had received various drugs and palliative irradiation, which was followed by nivolumab treatment, for renal cell carcinoma. Three days after the initial nivolumab administration, she presented with respiratory symptoms. On the basis of chest computed tomography findings, she was diagnosed with nivolumab-induced radiation recall pneumonitis and treated with prednisolone (1 mg/kg). The condition resolved rapidly, and chest computed tomography 4 months after nivolumab cessation revealed interval resolution of the lung consolidation and persistent tumor shrinkage.
Physicians should consider the risk of radiation recall pneumonitis during treatment with immune checkpoint inhibitors in patients who have received previous thoracic radiotherapy.
先前接受过放疗的肺部发生的放射回忆反应称为放射性肺炎。我们遇到了一例罕见的放射性肺炎病例,该病例由纳武单抗引起,发生在肋骨姑息性放疗9个月后。
患者为一名69岁的肾细胞癌女性。她因肾细胞癌接受了多种药物治疗和姑息性放疗,随后接受了纳武单抗治疗。首次使用纳武单抗3天后,她出现了呼吸道症状。根据胸部计算机断层扫描结果,她被诊断为纳武单抗诱导的放射性肺炎,并接受了泼尼松龙(1mg/kg)治疗。病情迅速缓解,纳武单抗停药4个月后的胸部计算机断层扫描显示肺部实变逐渐消退,肿瘤持续缩小。
对于先前接受过胸部放疗的患者,医生在使用免疫检查点抑制剂治疗期间应考虑放射性肺炎的风险。